Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Merlin,Jean-Louis; Harlé,Alexandre; Lion,Maëva; Ramacci,Carole; Leroux,Agnès

doi:10.3892/or.2013.2645

Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Authors:
- Jean-Louis Merlin
- Alexandre Harlé
- Maëva Lion
- Carole Ramacci
- Agnès Leroux
View Affiliations

Affiliations: Department of Biopathology, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre les Nancy, France
Published online on: July 30, 2013 https://doi.org/10.3892/or.2013.2645
Pages: 1943-1948

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MAP kinase signaling proteins have major implications in the molecular oncogenesis of breast cancers and have been extensively investigated as putative targets for therapy. This study reports the investigation of the expression of P38 MAPK and its phosphorylated form (p-P38 MAPK) in clinical specimens of invasive breast carcinomas and their correlation with estrogen receptor (ER) and HER2 expression, as well as MAPK and PI3 kinase-AKT pathway signaling phosphorylated proteins. Expression levels of P38 MAPK and p-P38 MAPK as well as p-AKT, p-GSK3β, p-S6 kinase, p-MEK1 and p-ERK1/2 were quantitatively assessed using multiplex bead immunoassay in frozen specimens from 45 invasive ductal breast cancers. Twenty-nine specimens were ER+, 15 were HER2+ and 10 were triple‑negative breast cancers (TNBCs). P38 MAPK was found to be expressed in all tumor specimens and was significantly (P=0.002) overexpressed in ER+ tumors. P38 MAPK expression was lower in TNBCs than in all of the other tumors. The median expression of p-P38 MAPK was also higher in ER+ tumors while lower in the TNBCs. HER2 status had no effect on P38 MAPK and p-P38 MAPK expression. No variation in the phosphorylation rate of P38 MAPK was observed in relation with ER, HER2 or TNBC status. Significantly higher (P=0.0048) expression of p-AKT was observed in HER2+ tumors. No significant difference in p-MEK1, p-GSK3β and p-S6K expression was found in any other comparisons based on ER and HER2 expression subtypes. Investigation of the expression of multiple phosphorylated signaling proteins can be used for personalized targeted therapy. In invasive breast cancer, the overexpression of P38 MAPK may serve as a biomarker for the evaluation of P38 MAPK inhibitors.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
3	Maemura M, Iino Y, Koibuchi Y, Yokoe T and Morishita Y: Mitogen-activated protein kinase cascade in breast cancer. Oncology. 57(Suppl 2): 37–44. 1999. View Article : Google Scholar
4	Ono K and Han J: The p38 signal transduction pathway: activation and function. Cell Signal. 12:1–13. 2000. View Article : Google Scholar
5	Frigo DE, Basu A, Nierth-Simpson EN, et al: p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol. 20:971–983. 2006. View Article : Google Scholar
6	Wagner EF and Nebreda A: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tang L and Han X: The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother. 67:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
8	Salh B, Marotta A, Wagey R, Sayed M and Pelech S: Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer. 98:148–154. 2002. View Article : Google Scholar : PubMed/NCBI
9	Esteva FJ, Sahin AA, Smith TL, et al: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 100:499–506. 2004. View Article : Google Scholar : PubMed/NCBI
10	Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005. View Article : Google Scholar
11	Davidson B, Konstantinovsky S, Kleinberg L, et al: The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 102:453–461. 2006. View Article : Google Scholar : PubMed/NCBI
12	Chen L, Mayer JA, Krisko TI, et al: Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 69:8853–8861. 2009. View Article : Google Scholar : PubMed/NCBI
13	Mueller KL, Powell K, Madden JM, Eblen ST and Boerner JL: EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK. Transl Oncol. 5:327–334. 2012. View Article : Google Scholar : PubMed/NCBI
14	Antoon JW, Bratton MR, Guillot LM, et al: Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res. 2:446–458. 2012.PubMed/NCBI
15	Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I and Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 126:545–562. 2010. View Article : Google Scholar : PubMed/NCBI
16	Normanno N, Di Maio M, De Maio E, et al: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005. View Article : Google Scholar : PubMed/NCBI
17	Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cortés J, Saura C, Bellet M, et al: HER2 and hormone receptor-positive breast cancer - blocking the right target. Nat Rev Clin Oncol. 8:307–311. 2011.PubMed/NCBI
19	Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68:826–833. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lee H and Bai W: Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol. 22:5835–5845. 2002. View Article : Google Scholar : PubMed/NCBI
21	Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
22	Chen J, Baskerville C, Han Q, Pan ZK and Huang S: α(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem. 276:47901–47905. 2001.
23	Kim MS, Lee EJ, Kim HR and Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 63:5454–5461. 2003.PubMed/NCBI
24	Qi X, Zhi H, Lepp A, et al: p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. J Biol Chem. 287:14681–14691. 2012.
25	Banerjee A, Koziol-White C and Panettieri R Jr: p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Curr Opin Pharmacol. 12:287–292. 2012.
26	Chergui F, Chrétien AS, Bouali S, et al: Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin Chem. 55:1327–1336. 2009. View Article : Google Scholar : PubMed/NCBI
27	Svensson S, Jirström K, Rydén L, et al: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene. 24:4370–4379. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bhatt S, Xiao Z, Meng Z and Katzenellenbogen BS: Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptor α turnover and functional activity via the SCF(Skp2) proteasomal complex. Mol Cell Biol. 32:1928–1943. 2012.
29	Meng F, Zhang H, Liu G, et al: p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. Neoplasia. 13:472–482. 2011.
30	Qi X, Hou S, Lepp A, et al: Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poison. J Biol Chem. 286:35883–35890. 2011.
31	Milde-Langosch K, Bamberger AM, Rieck G, et al: Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 92:2206–2215. 2005. View Article : Google Scholar : PubMed/NCBI
32	Linderholm BK, Hellborg H, Johansson U, Skoog L and Lehtiö J: Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor-positive breast cancer. Breast Cancer Res Treat. 125:457–465. 2011. View Article : Google Scholar
33	Hermanto U, Zong CS and Wang LH: Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Cell Growth Differ. 11:655–664. 2000.
34	Park SS and Kim SW: Activated Akt signaling pathway in invasive ductal carcinoma of the breast: Correlation with HER2 overexpression. Oncol Rep. 18:139–143. 2007.PubMed/NCBI